(177)Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model.

about

Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects.

P2860

Q50079728-09BEA004-16C8-40C2-895B-5C21EA94A1E0

P2860

(177)Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model.

Item

http://www.wikidata.org/entity/Q38853973

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

(177)Lu-OPS201 targeting somat ...... and dosimetry in a pig model.

@en

type

Item

label

(177)Lu-OPS201 targeting somat ...... and dosimetry in a pig model.

@en

prefLabel

(177)Lu-OPS201 targeting somat ...... and dosimetry in a pig model.

@en

P1476

(177)Lu-OPS201 targeting somat ...... n and dosimetry in a pig model

@en

P2093

Benedict Kjærgaard

http://www.w3.org/2001/XMLSchema#string

Hakim Bouterfa

http://www.w3.org/2001/XMLSchema#string

Jan S Dam

http://www.w3.org/2001/XMLSchema#string

Jens Kaufmann

http://www.w3.org/2001/XMLSchema#string

Romain Bejot

http://www.w3.org/2001/XMLSchema#string

Seval Beykan

http://www.w3.org/2001/XMLSchema#string

Svend Borup Jensen

http://www.w3.org/2001/XMLSchema#string

Uta Eberlein

http://www.w3.org/2001/XMLSchema#string

P2860

Dose translation from animal to human studies revisited

Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy.

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.

Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma

Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors.

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours

Peptide-receptor radionuclide therapy for endocrine tumors.

Tolerance of normal tissue to therapeutic irradiation.

Radiation Dosimetry Aspects of (177)Lu.

Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.

P2888

s13550-016-0204-9

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13550-016-0204-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Lars Jødal

Michael Lassmann

P577

2016-06-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1012360040

http://www.w3.org/2001/XMLSchema#string

P698

27294582

http://www.w3.org/2001/XMLSchema#string

P932

4906090

http://www.w3.org/2001/XMLSchema#string

(177)Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model.

about

P2860

P2860

(177)Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P932